Study Details
A Multiple Dose Escalation Study of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis
Clinicaltrials.gov ID
Astellas Study ID
7163-CL-0107
EudraCT ID
N/A
Condition
Psoriasis
Phase
Phase 2
Age
18 Years - 75 Years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Apr 2012 - Jan 2015
Masking
Double (Participant, Investigator)
Enrollment number
60
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Multiple Dose Escalation Study of ASKP1240 in Subjects with Moderate to Severe Plaque Psoriasis? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Specialist Connect
Brisbane, Australia, 4102
CMAX
Adelaide, Australia, 5000
Epworth Hospital
Richmond, Australia, 3121
Linear Research
Nedlands, Australia, 6009
Winnipeg Clinic
Winnipeg, Canada, R3C 0N2
Durondel C.P. Inc, The Dermatology Clinic
Moncton, Canada, E1C 8X3
New Lab Clinical Research
St. John's, Canada, A1C 2H5
Ultranova Skincare
Barrie, Canada, L4M 6L2
K. Papp Clinical Research
Waterloo, Canada, N2J 1C4
Innovaderm Research, Inc.
Montreal, Canada, H2K 4L5
Auckland Clinical Studies
Auckland, New Zealand, 1010
Christchurch Clincial Studies Trust, Ltd.
Christchurch, New Zealand, 8011
P3 Research, Tauranga
Tauranga, New Zealand, 3110
P3 Research, Wellington
Wellington, New Zealand, 6021